Evidence map›Paper›PMID 41094553›Full record

ArticleBMC medicine2025

Extracellular vesicles derived from menstrual blood-derived mesenchymal stem cells suppress inflammatory atherosclerosis by inhibiting NF-κB signaling.

Jinjin Yu, Xiaotian Liu, Lele Jin, Han Li, Suhui Wang, Yongwei Yang, Xilian Chen, Hongxia Wang, Yingke Li, Jie Lian and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jinjin Yu *Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, First Affiliated Hospital, Bengbu Medical University, Bengbu, 233004, China.
Xiaotian Liu *Research Center of Clinical Laboratory Science, School of Laboratory Medicine, Bengbu Medical University, Bengbu, 233004, China.
Lele Jin *Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, Bengbu Medical University, 287 Changhuai Road, Bengbu, Anhui Province, 233004, China.
Han Li *National Joint Engineering Laboratory of Stem Cells and Biotherapy, School of Life Science and Technology, Stem Cells and Biotherapy Engineering Research Center of Henan, Xinxiang Medical University, Xinxiang, 453003, China.
Suhui WangAnhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, First Affiliated Hospital, Bengbu Medical University, Bengbu, 233004, China.
Yongwei YangYantai Qishan Hospital, Yantai, 264001, China.
Xilian ChenYantai Qishan Hospital, Yantai, 264001, China.
Hongxia WangCao County Infectious Disease Hospital, Heze, 274000, China.
Yingke LiHenan Joint International Research Laboratory of Stem Cell Medicine, College of Biomedical Engineering, Xinxiang Medical University, Xinxiang, 453003, China.
Jie LianHenan Joint International Research Laboratory of Stem Cell Medicine, College of Biomedical Engineering, Xinxiang Medical University, Xinxiang, 453003, China.
Chao ShiDepartment of Cardiac Surgery, First Affiliated Hospital, Bengbu Medical University, Bengbu, 233004, China.
Haihui LiDepartment of Cardiac Surgery, First Affiliated Hospital, Bengbu Medical University, Bengbu, 233004, China.
Yong ZhangDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital, Bengbu Medical University, 287 Changhuai Road, Bengbu, Anhui Province, 233004, China.
Emmanuel Jairaj MosesRegenerative Medicine Sciences Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, 13200, Malaysia. emmanuel_jm@usm.my.
Hongxing ZhangSchool of Psychology, Xinxiang Medical University, Xinxiang, 453003, China. zhanghxzhang@hotmail.com.
Chunfu ZhengDepartment of Microbiology, Immunology & Infection Diseases, Health Research Innovation Centre, University of Calgary, 3330 Hospital Drive NW, CalgaryAlberta, AB, T2N 4N1, Canada. zheng.alan@hotmail.com.
Xinxing ZhuDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital, Bengbu Medical University, 287 Changhuai Road, Bengbu, Anhui Province, 233004, China. 012023112@bbmc.edu.cn.

Funding

National Natural Science Foundation of China 81900392Translational Project in Clinical Medical Research 202304295107020074
6 · The paper itself

Abstract

backgroundNumerous studies have highlighted the beneficial effects of mesenchymal stem cells (MSCs) in various inflammatory disorders. However, the regulatory role of MSCs in inflammatory atherosclerosis and the molecular mechanisms underlying their anti-inflammatory properties have largely remained elusive.

methodsDifferential ultracentrifugation was performed to isolate extracellular vesicles (EVs) released by menstrual blood-derived mesenchymal stem cells (MenSCs). An ApoE knockout atherosclerotic animal model was employed to investigate the regulatory effect of MenSC-EVs on inflammatory atherosclerosis. miRNA microarray screening analyses were conducted to identify potential effectors in MenSC-EVs that play a key role in the suppression of atherosclerosis mediated by the EVs.

resultsWe demonstrated the remarkable potential of MenSC-EVs in alleviating atherosclerosis through the NF-κB signaling pathway. miR-574-5p serves as a crucial effector molecule transported by MenSC-EVs, suppressing endothelial inflammation and promoting nitric oxide production. This regulation contributes to the attenuation of atherosclerosis by regulating the abundance of c-Rel. The miR-574-5p/c-Rel axis shows significant clinical relevance to atherosclerosis.

conclusionsThis study reveals that the engineering of EVs derived from MenSCs holds significant promise as a strategic clinical approach for addressing inflammatory atherosclerosis.

Indexed as

AtherosclerosisExtracellular VesiclesMenstruationMesenchymal Stem CellsNF-kappa BAnimalsFemaleHumansInflammationMiceMicroRNAsSignal TransductionMicroRNAsNF-kappa BExtracellular vesiclesInflammatory atherosclerosisMenSCsMiR-574-5pNF-κB signaling

Identifiers

PMID41094553
PMCPMC12522235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.